Please login to the form below

risankizumab

This page shows the latest risankizumab news and features for those working in and with pharma, biotech and healthcare.

AbbVie’s Crohn’s disease drug given green light by MHRA

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a positive opinion under the Early Access to Medicines Scheme (EAMS) for AbbVie’s risankizumab. ... Having risankizumab available via the early access scheme is a positive

Latest news

Janssen’s Tremfya receives positive results for active psoriatic arthritis

These involved 15 unique treatments, including IL-23 inhibitors – guselkumab and risankizumab – subcutaneous tumour necrosis factor inhibitors and Janus kinase inhibitors. ... Regarding an improvement in joint inflammation, both Tremfya dosing
Lilly reports positive data from its phase 3 ulcerative colitis trial

For Crohn’s, mirikizumab is in a close race with AbbVie’s IL-23 inhibitor Skyrizi (risankizumab), which recently met both primary endpoints of clinical remission and endoscopic response at week
Skyrizi, Rinvoq help AbbVie weather Humira slowdown

news. Quick take-up of new immunology drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) have encouraged AbbVie to predict the pair will together make around $1.7bn in sales this year, well
Cosentyx, Entresto drive topline growth for Novartis in Q4

However, in head-to-head trials with both AbbVie’s Humira (adalimumab) and Skyrizi (risankizumab), Cosentyx failed to show superiority – a potential sign of trouble ahead as the psoriasis/biologic market
AbbVie lauds head-to-head win for Skyrizi versus Cosentyx

Skyrizi. The head-to-head study pitted IL-23 antagonist Skyrizi (risankizumab) against Novartis’ blockbuster IL-17 inhibitor Cosentyx (secukinumab) – which has sales currently running at around $1bn a quarter – and

More from news
Approximately 4 fully matching, plus 28 partially matching documents found.

Latest Intelligence

20 for 2020 – Five pharma companies to watch

AbbVie needs its new products to deliver quickly, and that includes recently approved JAK inhibitor Rinvoq (upadacitinib) for arthritis and psoriasis therapy Skyrizi (risankizumab) – both tipped as possible future blockbusters despite
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

Sales are projected at $1.93bn for 2013. Skyrizi (risankizumab) treats psoriasis.
Drug launches to watch in 2019

It announced the filing of upadacitinib in the US and Europe on 20 December, with the filing of risankizumab expected early this year. ... The analysis showed that 56% of patients on risankizumab were symptom-free after a year’s treatment, compared to